Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Child & Adolescent Psychiatry
Published in: European Child & Adolescent Psychiatry 9/2016

01-09-2016 | Letter to the Editor

Response to: The evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder is in fact flawed

Authors: Pieter J. Hoekstra, Jan K. Buitelaar

Published in: European Child & Adolescent Psychiatry | Issue 9/2016

Login to get access

Excerpt

In our editorial [1] on the evidence base of methylphenidate, we made a number of critical comments to the Cochrane review [3], to which the authors have responded. While we thank the authors for their reaction, we would like to take the opportunity to explain our critique. …
Literature
1.
Hoekstra PJ, Buitelaar JK (2016) Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed? Eur Child Adolesc Psychiatry 25(4):339–340CrossRefPubMed
2.
Sterne JA (2013) Why the Cochrane risk of bias tool should not include funding source as a standard item. Cochrane Database Syst Rev 12
3.
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C (2015) Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. doi:10.​1002/​14651858.​CD009885.​pub2 PubMed
Metadata
Title
Response to: The evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder is in fact flawed
Authors
Pieter J. Hoekstra
Jan K. Buitelaar
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
European Child & Adolescent Psychiatry / Issue 9/2016
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI
https://doi.org/10.1007/s00787-016-0856-z

Other articles of this Issue 9/2016

European Child & Adolescent Psychiatry 9/2016 Go to the issue

Original Contribution

Leptin levels in patients with anorexia nervosa following day/inpatient treatment do not predict weight 1 year post-referral

Original Contribution

A 6-year follow-up of a large European cohort of children with attention-deficit/hyperactivity disorder-combined subtype: outcomes in late adolescence and young adulthood

Original Contribution

Bidirectional association between autism spectrum disorder and epilepsy in child and adolescent patients: a population-based cohort study

Original Contribution

Do neurocognitive deficits in decision making differentiate conduct disorder subtypes?

Letter to the Editor

The evidence base of methylphenidate for children and adolescents with attention-deficit hyperactivity disorder is in fact flawed

Original Contribution

Gray matter volumes in symptomatic and asymptomatic offspring of parents diagnosed with bipolar disorder